Pulmonary Function Testing (PFT) is a vital tool in diagnosing and managing respiratory diseases. However, interpreting the results can be complex for healthcare professionals. This guide aims to simplify the process.
Spirometry, the most common PFT, measures the amount (volume) and speed (flow) of air that can be inhaled and exhaled. Key values include Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and their ratio (FEV1/FVC). Abnormalities in these values can indicate obstructive or restrictive lung diseases.
Obstructive disorders, such as COPD and asthma, are characterized by reduced airflow. This is reflected in a decreased FEV1/FVC ratio. On the other hand, restrictive disorders like pulmonary fibrosis present with reduced lung volumes (FVC), but normal or increased FEV1/FVC ratio.
Gas exchange tests, such as the diffusion capacity for carbon monoxide (DLCO), provide insight into the lung’s ability to transfer gases between the alveoli and the bloodstream. Reduced DLCO can indicate diseases like emphysema or pulmonary hypertension.
Interpretation of PFT results should always be integrated with the patient's symptoms, physical examination, and other diagnostic tests. For instance, a reduced FEV1/FVC ratio accompanied by wheezing and episodic breathlessness may suggest asthma.
Interpreting PFT results is a nuanced process that requires a comprehensive understanding of respiratory physiology and clinical context. By understanding spirometry and gas exchange testing, and recognizing obstructive and restrictive patterns, healthcare professionals can more accurately diagnose and manage respiratory diseases.
1.
Global warming could be driving up women's cancer risk, find researchers
2.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
3.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
4.
MRI can save rectal cancer patients from surgery, study suggests
5.
Glioma Outcomes Shaped by Subtype More Than Tx Sequence
1.
Rehabilitation After Organ-Conserving Cancer Surgery
2.
Practical Breakthroughs in Oncology Across Clinical Settings
3.
Gynecologic Oncology: Advances, Education, and Clinical Excellence
4.
Breaking Down the Different Types of Lymphoma: What You Need to Know
5.
RNA-Targeting Chimeras in Cancer: Mechanisms, Clinical Advances, and Future Directions
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Cancer Care: From Awareness to Recovery
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation